Dapagliflozin - a new class of drug to treat type 2 reduces reabsorption of glucose in the kidneys has been shown to be safe and effective in a phase III trial led by UK researchers.
It suppresses activity of a protein called SGLT2, which is responsible for the majority of glucose reabsorption in the kidney.
http://www.pulsetoday.co.uk/story.asp?sectioncode=23&storycode=4126458&c=2
Other news:
Metabolic syndrome linked with microvascular disease in diabetes
http://www.incirculation.net/NewsIt...-with-microvascular-disea.aspx?usechannel=DIA
Triple-Combination Therapy Significantly Reduces BP in Patients With Diabetes, Hypertension: Presented at ADA
http://main.pslgroup.com/news/content.nsf/MedicalNews/852576140048867C85257753006E1C0F
Inhaled insulin 'as good as standard therapy'
http://www.pulsetoday.co.uk/story.asp?sectioncode=23&storycode=4126449&c=2
It suppresses activity of a protein called SGLT2, which is responsible for the majority of glucose reabsorption in the kidney.
http://www.pulsetoday.co.uk/story.asp?sectioncode=23&storycode=4126458&c=2
Other news:
Metabolic syndrome linked with microvascular disease in diabetes
http://www.incirculation.net/NewsIt...-with-microvascular-disea.aspx?usechannel=DIA
Triple-Combination Therapy Significantly Reduces BP in Patients With Diabetes, Hypertension: Presented at ADA
http://main.pslgroup.com/news/content.nsf/MedicalNews/852576140048867C85257753006E1C0F
Inhaled insulin 'as good as standard therapy'
http://www.pulsetoday.co.uk/story.asp?sectioncode=23&storycode=4126449&c=2
